Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 209

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 209
---
 June 30, 2025 and 2024 (in thousands):

June 30, 2025ReturnsAllowancesPromptPaymentDiscountsServiceFeesVolumeRebates andChargebacksGovernmentRebatesTotalBalance at December 31, 2024$1,600 $1,308 $4,875 $4,863 $1,707 $14,353 Provision702 6,918 11,189 76,044 1,813 96,666 Payments(267)(6,838)(11,320)(76,113)(1,815)(96,353)Balance at June 30, 2025$2,035 $1,388 $4,744 $4,794 $1,705 $14,666 

June 30, 2024ReturnsAllowancesPromptPaymentDiscountsServiceFeesVolumeRebates andChargebacksGovernmentRebatesTotalBalance at December 31, 2023$1,868 $1,308 $3,697 $5,870 $1,175 $13,918 Provision1,014 6,199 9,985 54,533 1,334 73,065 Payments(664)(6,287)(9,850)(55,058)(715)(72,574)Balance at June 30, 2024$2,218 $1,220 $3,832 $5,345 $1,794 $14,409 

Total reductions of gross product sales from sales-related allowances and accruals were $96.7 million and $73.1 million, or 21.7% and 17.6% of gross product sales, for the six months ended June 30, 2025 and 2024, respectively. The overall 4.1% increase in sales-related allowances and accruals as a percentage of gross product sales was primarily related to accruals as a result of higher chargeback-related allowances from expanded contracting efforts.

Cost of Goods Sold 

Cost of goods sold primarily relates to the costs to produce, package and deliver our products to customers. These expenses include labor, raw materials, manufacturing overhead and occupancy costs, depreciation of facilities, quality control and engineering. In 2024, the cost of royalty payments were also a component of cost of goods sold. 

The following table provides information regarding our cost of